Enveric Biosciences (NASDAQ:ENVB) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, a prodrug of psilocin being developed for the treatment of depression and anxiety disorders. The patent, titled 'C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,' includes claims for a family of novel prodrug derivatives of psilocin, including EB-373. The company has filed multiple patent applications for psilocin prodrugs and has submitted additional filings for companion Patent Cooperation Treaty and non-US national patent applications.